HomeFUNDING

Category: FUNDING

Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.

Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.

E Tech Group Secures New...

April 11, 2024

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.

ROM InWest Invests €1.5 million...

April 10, 2024

The investment will allow ROM InWest to further distribute its fall detection product globally.

E Tech Group Secures New Investment from Graham Partners, Sets Stage for Continued Growth and Innovation

April 11, 2024

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.

Neurolief Announces Strategic Equity Investment by Sawai Group Holdings

Mitsuo Sawai, CEO of Sawai Group Holdings, highlighted their commitment to improving patient care and expanding treatment options for migraine and depression through the introduction of Relivion® for at-home treatment under doctor supervision.

December 28, 2023

LUMA Vision Announces $22 Million in New Financing to Secure FDA Approval and Advance Development of 4D Cardiac Imaging and Navigation Platform

The Series A3 financing added three new investors comprising an undisclosed multinational strategic investor, Atlantic Bridge Growth Fund and Bayern Kapital, and was led by existing investors EQT Lifesciences, ABV Uni Fund and imec.xpand. The new funding adds to prestigious grants won earlier by LUMA Vision from the Irish government’s Disruptive Technologies Innovation Fund ($6 million) and the European Union’s EIC Accelerator ($3 million).

December 18, 2023

Kazia Therapeutics Announces $2 Million Registered Direct Offering

Kazia has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs. The warrants will have an exercise price of $0.583 per ADS, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about December 5, 2023, subject to the satisfaction of customary closing conditions.

December 1, 2023

Savage Medical Exits Stealth With Over $3 Million to Enable Minimally Invasive Colorectal Tumor Removal

The groundbreaking ColoSeal System™ enables minimally invasive colorectal tumor removal, eliminating the need for 2 open surgeries in today's standard of care notes Savage Medical.

November 29, 2023

Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing

Alto Neuroscience advises the funds will be used to support ongoing and planned late-stage clinical development of CNS product candidates with four Phase 2 readouts expected across the next 12-18 month

November 21, 2023

Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles

Micron Biomedical has received this grant from the Bill & Melinda Gates Foundation to fund mass production of needle-free vaccines utilizing Micron technology to expand the accessibility of measles-rubella vaccine in developing countries

November 16, 2023

Cromatic Closes $5.3 Million in Oversubscribed Seed Round to Modernize Life Science R&D Outsourcing

Ann Lin, co-founder and CEO of Cromatic said, "Outsourcing R&D is one of the most powerful ways for innovative biotech companies to get off the ground. While founders of tech giants like Apple and Google could build their products in garages with minimal resources, founders in biotech are confronted with the capital expense of lab space and equipment and the lengthy process of building the right team before they can even test their ideas. That’s why we are building the most powerful R&D outsourcing platform for biotechs, so that scientists will have clarity, confidence and choice when evaluating and managing their service providers. Ultimately, we want to enable biotech companies to start in garages, just like tech giants.”

November 9, 2023

Access Vascular to Ramp Production With $22 Million Series C Financing

The financing will support a substantial production capacity increase for the unique MIMIX™ hydrophilic biomaterial vascular access devices developed by AVI, which are designed to evade the foreign body reaction by mimicking the human body’s natural chemistry, as well as further research into the potential for MIMIX to lower catheter infection rates, and expansion of AVI’s product portfolio notes Access Vascular.

October 31, 2023

Neteera raises an additional $6.7M Series B Extension

Neteera raised the first $13 million in April 2023 in a round led by Aescuvest, which led this extension as well. Foxconn Technology joined.

October 31, 2023